Form 4 for MAZE Maze Therapeutics, Inc.
Accepted 2026-07-01 16:17:19 ET · period of report 2026-06-29 · accession 0002050167-26-000016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-01 16:17 | 2026-06-29 | MAZE | Dandekar Atul | CSBO | M - OptEx | $10.42 | +7,500 | 33.8K | +29% | +$78.2K |
| DT | 2026-07-01 16:17 | 2026-06-29 | MAZE | Dandekar Atul | CSBO | S - Sale+OE | $28.02 | -7,500 | 26.2K | -22% | -$210.2K |
| DT | 2026-07-01 16:17 | 2026-06-29 | MAZE | Dandekar Atul | CSBO | M - OptEx | $0.00 | -7,500 | 29.1K | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-29 | M | A | 7,500 | $10.42 | 33,750 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. (F2) The reported total includes 1,442 shares of the Issuer's Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). |
| 2 | Common | Common Stock | 2026-06-29 | S | D | 7,500 | $28.02 | 26,250 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-06-29 | M | D | 7,500 | $0.00 | 29,143 | D | $10.42 · — to 2031-04-11 | 7,500 Common Stock | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. (F3) The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. |